Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier.

AUTOR(ES)

Saga, T

RESUMO

Monoclonal antibodies penetrate bulky tumors poorly after intravenous administration, in part because of specific binding to the target antigen. Experiments presented here demonstrate an analogous phenomenon in micrometastases; poor antibody penetration, attributable to a "binding-site barrier" phenomenon, can be seen in guinea pig micrometastases as small as 300 microns in diameter. Increasing the dose of antibody can partially overcome this limitation, but at a cost in specificity.

Documentos Relacionados

• Excited-state intramolecular proton transfer as a fluorescence probe for protein binding-site static polarity
• Genomic binding-site cloning reveals an estrogen-responsive gene that encodes a RING finger protein.
• Excited-state intramolecular proton transfer as a fluorescence probe for protein binding-site static polarity.
• The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice
• Kinetic and Equilibrium Analysis of Estradiol in Uterus: A Model of Binding-Site Distribution in Uterine Cells